Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 9/20 | 0.59 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360673 | 1.00 | KLK7 (0.59) | KLK7PTGESALOX5PPARGCYP1A2 | |
| SCHEMBL359760 | 0.91 | KLK7 (0.57) | KLK7PPARGCYP1A2CYP2D6LMNA | |
| SCHEMBL359759 | 0.91 | KLK7 (0.57) | KLK7PPARGCYP1A2CYP2D6LMNA | |
| SCHEMBL360652 | 0.84 | KLK7 (0.68) | KLK7CYP1A2CYP2D6LMNACHRM1 | |
| SCHEMBL360653 | 0.84 | KLK7 (0.68) | KLK7CYP1A2CYP2D6LMNACHRM1 | |
| SCHEMBL9215034 | 0.81 | NAAA (0.51) | KLK7LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL359777 | 0.80 | PPARG (0.51) | KLK7PPARGCHRM1CHRM3CHRM2 | |
| SCHEMBL359778 | 0.80 | PPARG (0.51) | KLK7PPARGCHRM1CHRM3CHRM2 | |
| SCHEMBL361291 | 0.78 | KLK7 (0.54) | KLK7CYP1A2CYP2D6LMNACHRM1 | |
| SCHEMBL361290 | 0.78 | KLK7 (0.54) | KLK7CYP1A2CYP2D6LMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407447-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER | TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-8552215-B2 | Method for producing optically active 2-hydroxy ester and novel intermediate compound | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2407447-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | Tokyo University Of Science Educational Foundation Administrative Organization (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319650-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319650-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | CA7, HAO2, HACL2 | KLK7 3948/4885PTGES 1391/4885ALOX5 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.